Advertisement
UK markets closed

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • FTSE 250

    20,164.54
    +112.21 (+0.56%)
     

  • AIM

    771.53
    +3.42 (+0.45%)
     

  • GBP/EUR

    1.1652
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2546
    +0.0013 (+0.11%)
     

  • Bitcoin GBP

    49,899.96
    +2,752.64 (+5.84%)
     

  • CMC Crypto 200

    1,363.86
    +86.88 (+6.80%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,475.92
    +268.79 (+1.48%)
     

  • DAX

    18,001.60
    +105.10 (+0.59%)
     

  • CAC 40

    7,957.57
    +42.92 (+0.54%)
     
MONEY:

Best savings accounts that offer above inflation rates

Where to find a top-rated deal that works for you

Roche gets European marketing approval for cancer treatment Rozlytrek

Reuters
FILE PHOTO: Logo of Swiss drugmaker Roche is seen in Basel

ZURICH (Reuters) - Pharmaceuticals company Roche <ROG.S> said on Monday it had been granted conditional European marketing approval for its Rozlytrek drug to treat people with hard to treat types of cancer.

The drug has been approved for patients older than 12 with solid tumours in an advanced form of the disease, and where surgery is likely to lead to further complications.

The European Commission has also approved Rozlytrek for the treatment of adults with a form of advanced non-small cell lung cancer, the company said.

(Reporting by John Revill; Editing by Jacqueline Wong)